Top Tweets for #nmhspc
Macroscopic local relapse after RP in the context of high-risk #nmHSPC. Presentation by @PCaParker @royalmarsdenNHS. #EAU26 written coverage by @RKSayyid @UAUrology > https://t.co/ogdFusOcGv @Uroweb

🚩Do not miss these #CUA24 Educational Sessions featuring Brita Danielson, @UroOncMD, Christian Kollmannsberger, @wayne_brisbane, Bobby Shayegan, Hanmu Yan. 🚩Reserve your spot today >>> https://t.co/cMHALbepR4
#nmHSPC #prostatecancer #AI

🚩Do not miss these #CUA24 Educational Sessions featuring Brita Danielson, @UroOncMD, Christian Kollmannsberger, @wayne_brisbane, Bobby Shayegan, Hanmu Yan. 🚩Reserve your spot today >>> https://t.co/cMHALbdS1w
#nmHSPC #prostatecancer #AI

Global QOL was not meaningfully impacted by enzalutamide suspension in in patients with biochemically recurrent #nmHSPC responding well to enzalutamide, according to a data from the phase 3 EMBARK trial presented at #ASCO24. @SFreedlandMD @CSCancerCenter
https://t.co/FGnZyJ6K0g
The #ROAR study showed that #rucaparib had an acceptable safety & efficacy profile as an ADT-sparing approach in pts w/ high-risk biochemically recurrent #nmHSPC w/ #BRCA 1/2 or other homologous recombination repair mutations. @neerajaiims @maughanonc https://t.co/gtVZyJYzE5

経口アンドロゲン受容体阻害薬 #エンザルタミド について、生化学的再発のリスクが高い #非転移性去勢感受性前立腺がん(#nmCSPC、#nmHSPC)への適応拡大が米国で承認されました。
https://t.co/rXafTLL96A
Enzalutamide + leuprolide showed promise in patients with #nmHSPC with high-risk biochemical recurrence vs leuprolide alone, according to findings from the phase 3 EMBARK trial. #pcsm | @Dan_Theodorescu @CedarsSinaiMed
https://t.co/IzinhThhW8
#EMBARK: Health-related quality of life in #nmHSPC patients with high-risk BCR. Presentation by @SFreedlandMD @CedarsSinai. #ESMO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/Mu8gK3NFq1 @myESMO

PSMA PET findings in an “EMBARK-like” cohort of pts with high-risk #nmHSPC: a single center posthoc retrospective analysis. Presented by Wesley Armstrong @uclacaltechmstp. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/39xOmo58zi @ASCO

The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/YlufsDI3mW @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/lqQhrMyWRM @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/YlufsDIBcu @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK study: A phase 3 randomized study of enzalutamide + leuprolide and enzalutamide monotherapy in HR #nmHSPC with rising PSA after local therapy @SFreedlandMD @CSCancerCare. #WatchNow > https://t.co/19ihyEoaWJ @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open

The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/lqQhrMQxJk @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK study: A phase 3 randomized study of enzalutamide + leuprolide and enzalutamide monotherapy in HR #nmHSPC with rising PSA after local therapy @SFreedlandMD @CSCancerCare. #WatchNow > https://t.co/19ihyEFLOh @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open

The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/YlufsDI3mW @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK study: A phase 3 randomized study of enzalutamide + leuprolide and enzalutamide monotherapy in HR #nmHSPC with rising PSA after local therapy @SFreedlandMD @CSCancerCare. #WatchNow > https://t.co/19ihyEoaWJ @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open

The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/lqQhrMzuHk @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
Last Seen Hashtags on Sotwe
dreamybull
Seen from Brazil
teenagergirls() +filter:native_video
Seen from United States
esrarabiaünal
Seen from Turkey
amateurmilf
Seen from Switzerland
Jadenwalton
นวดรามอินทรา
Seen from Thailand
รับงานบางบ่อ
Seen from Thailand
Milky
Seen from Indonesia
cder
Seen from Indonesia
ometv
Seen from Singapore
Most Popular Users

Elon Musk 
@elonmusk
240.6M followers

Barack Obama 
@barackobama
119.2M followers

Donald J. Trump 
@realdonaldtrump
111.7M followers

Cristiano Ronaldo 
@cristiano
110.6M followers

Narendra Modi 
@narendramodi
107M followers

Rihanna 
@rihanna
97.7M followers

NASA 
@nasa
92.2M followers

Justin Bieber 
@justinbieber
90.9M followers

KATY PERRY 
@katyperry
87.7M followers

Taylor Swift 
@taylorswift13
81.5M followers

Lady Gaga 
@ladygaga
73.1M followers

Virat Kohli 
@imvkohli
69.9M followers

Kim Kardashian 
@kimkardashian
69.8M followers

YouTube 
@youtube
68.7M followers

Bill Gates 
@billgates
63.9M followers

Neymar Jr 
@neymarjr
62.7M followers

The Ellen Show
@theellenshow
62.4M followers

CNN 
@cnn
61.9M followers

X 
@x
60.8M followers

Selena Gomez 
@selenagomez
60.8M followers













